Compare Merck & Co., Inc. (MRK) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Sprott Uranium Miners ETF — how do they compare? Merck & Co., Inc. trades at $133.47 (market cap $321.77B), while Sprott Uranium Miners ETF trades at $55.51. The key difference: Merck & Co., Inc. pays a 2.61% dividend while Sprott Uranium Miners ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals.
| MRK | URNM | |
|---|---|---|
Market Cap | $321.77B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $131.84 | $83.99 |
52-Week Low | $77.60 | $44.14 |
Enterprise Value | $368.53B | — |
Dividend Yield | 2.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
URNM trades at $55.97, up 2.51% today, with a bullish technical signal driven by moving averages. The ETF focuses on uranium miners, benefiting from nuclear energy's resurgence. Recent news highlights significant government funding and AI-driven power demand as catalysts. Key support is at $55, with resistance at $56.
The outlook is positive due to structural uranium supply deficits and growing nuclear adoption, but risks include volatility from spot price swings and concentrated miner exposure. Analyst sentiment is mixed, with some favoring pure-miner exposure while others caution on valuation gaps versus underlying uranium prices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
